Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Pentoxifylline · Trental, BL-191

Small molecule · Inhibitor of phosphodiesterase · developed by Validus Pharms

Approved FDA, Aug 1984
1 Registered trials

What is Pentoxifylline?

Pentoxifylline is a methylxanthine derivative that inhibits phosphodiesterase, increasing cAMP levels to improve blood flow and erythrocyte flexibility. It reduces platelet aggregation and inhibits TNF-alpha and interferon-gamma production while promoting Th2 cytokine responses. It is studied in chronic kidney disease with hemodialysis for inflammation and protein-energy malnutrition.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Trental, BL-191, pentoxiphylline
Drug type
Small molecule
Targets
phosphodiesterase, TNF-alpha (TNF) (secondary target), interferon-gamma (IFNG) (secondary target)
Mechanism
Inhibitor of phosphodiesterase
Pathways
cAMP signaling, vasodilation, platelet aggregation inhibition, Th1/Th2 balance
Therapy area
Renal & urology
Developer
Validus Pharms
In trials of
DVA
FDA status
Approved as Trental (August 30, 1984), NDA018631
UNII
SD6QCT3TSU

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT00561093 Phase 3 Hypoalbuminemia Completed DVA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Chronic Kidney Disease (CKD) HemodialysisHypoalbuminemiaInflammationOxidative StressProtein-energy Malnutrition

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.